Treatment
CAR-T cells clinical trials
We’re tracking 534 recruiting studies that include CAR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT07003555RecruitingPhase 1
Dual-target CAR-T therapy for multiple myeloma with extramedullary disease
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
ShanghaiAges 18–75 - NCT07022964RecruitingPhase 1/Phase 2
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
BeijingAges 14–70 - NCT07032129RecruitingPhase 1/Phase 2
Targeted cell therapy for multiple myeloma that returned or didn't respond
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Beijing, Beijing MunicipalityAges 21–90 - NCT07067255RecruitingPhase 1/Phase 2
Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
Beijing, Beijing MunicipalityAges 21–90 - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT07078929RecruitingPhase 1
CAR T-cell therapy for children with relapsed or refractory ALL
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
Bangkok, BangkoknoiAges 1–18 - NCT07085559RecruitingEarly Phase 1
Metabolically armed BCMA CAR-T for relapsed plasma cell cancer
This trial tests a new type of CAR-T cell therapy (Meta10-BCMA) that is "metabolically armed" to better fight cancer cells. It's for people with plasma cell cancers that have come back or not responded to multiple prior treatments, and whose cancer cells carry the BCMA protein.
Hefei, AnhuiAges 19–75 - NCT07097207RecruitingPhase 1/Phase 2
Study of CD19CD20-CAR-T for B-cell lymphoma
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07106684RecruitingPhase 2
Stem cell transplant with car-t and bi-specific antibody for plasma cell leukemia
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07135466RecruitingPhase 1/Phase 2
Anti-CD22 CAR T-cell therapy for B-cell blood cancers
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
Ramat Gan, GAges 1–80 - NCT07148791RecruitingPhase 2
CAR-T therapy for relapsed or refractory IgG4-related disease
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
Beijing, Beijing MunicipalityAges 18–75 - NCT07164560RecruitingPhase 1
CAR-NK cell therapy for relapsed T-cell lymphoma
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07181720RecruitingPhase 1
CD70-targeted CAR-T therapy for advanced solid tumors
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07193628RecruitingPhase 1
A new immune cell therapy for recurrent glioblastoma
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07193667Recruiting
CAR-T therapy for autoimmune diseases
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Shenyang, LiaoningAges 18–65 - NCT07193966RecruitingPhase 1/Phase 2
CAR-T cell therapy for advanced melanoma using NG2 and DLL3 targets
This trial tests a new treatment using your own immune cells (CAR-T cells) that are modified to find and attack melanoma cells with specific markers called NG2 and DLL3. It is for people whose melanoma has spread or come back after standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07233642RecruitingPhase 1
Fast CD19 CAR-T therapy for lupus not helped by standard treatment
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT07246304RecruitingEarly Phase 1
Cell therapy for DLL3-positive small cell lung cancer
This trial tests a new cell therapy called TC-D101 for people with a type of small cell lung cancer that has DLL3 protein on its surface. It may be an option if standard treatments have stopped working or are not suitable.
Nanjing, JiangsuAges 18–75 - NCT07249879RecruitingPhase 1
CAR-T cell therapy for DLL3-positive small cell lung cancer
This trial tests a new CAR-T cell therapy (GC511B) for people with a specific type of small cell lung cancer that has DLL3 protein. The treatment uses your own immune cells to target and attack the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07681388Recruiting
CAR-T cell therapy for hard-to-treat pemphigus
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
Wuhan, HubeiAges 18–70 - NCT07257640RecruitingPhase 1
IL-5 CAR-T therapy for eosinophilic leukemia
This phase 1 trial tests a new treatment called IL-5 CAR-T for patients with eosinophilic leukemia that has not responded to or has returned after standard therapy. It uses your own immune cells that are modified to target and kill cancer cells that have a specific marker called CD125.
Hangzhou, ZhejiangAges 18 years+ - NCT07261163RecruitingPhase 2
Combination therapy for first-line mantle cell lymphoma
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
Tianjin, Tianjin MunicipalityAges 18–80
Common questions
- Are there clinical trials studying CAR-T cells?
- Yes. Clin2 currently lists 534 recruiting studies that include CAR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CAR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CAR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CAR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.